Related Experiment Video
Updated: Aug 11, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
COX-2 inhibitors act as radiosensitizer in tumor treatment
Abstract:
Since cyclooxygenase-2 (COX-2) is overexpressed in malignant tissues, the COX-2 mediated signaling pathway has been recognized as potential target for therapeutic intervention. In most human tumors, COX-2 overexpression has been associated with tumor aggressiveness and poor clinical outcome. In vitro studies show inhibition of cell proliferation by selective COX-2 inhibitors alone, and enhancement of the response to irradiation. In vivo experimental reports demonstrate enhanced tumor response and impediment of tumor neovascularization following radiotherapy combined with COX-2 inhibition. Clinical studies on the combination of irradiation with COX-2 inhibitors are emerging. Taken together, the perspective for the combined approach of radiotherapy with COX-2 inhibition yields clinical significance since preclinical data demonstrate selective COX-2 inhibitors to act as radiosensitizer in tumor treatment.
Insights
Selective cyclooxygenase-2 (COX-2) inhibitors enhance radiotherapy efficacy by acting as radiosensitizers. Preclinical data show combined COX-2 inhibition and irradiation impede tumor growth and neovascularization, suggesting clinical significance.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy
Background:
- Cyclooxygenase-2 (COX-2) is overexpressed in malignant tissues, correlating with tumor aggressiveness and poor prognosis.
- The COX-2 signaling pathway is a recognized target for cancer therapeutic intervention.
Purpose of the Study:
- To evaluate the potential of selective COX-2 inhibitors as radiosensitizers in cancer treatment.
- To assess the combined effects of radiotherapy and COX-2 inhibition on tumor response and neovascularization.
Main Methods:
- In vitro studies assessing cell proliferation inhibition by COX-2 inhibitors and their effect on irradiation response.
- In vivo experiments evaluating tumor response and neovascularization following combined radiotherapy and COX-2 inhibition.
Main Results:
- Selective COX-2 inhibitors alone inhibited cancer cell proliferation in vitro.
- Combined radiotherapy and COX-2 inhibition demonstrated enhanced tumor response and reduced neovascularization in vivo.
- Emerging clinical studies are investigating this combined therapeutic approach.
Conclusions:
- Preclinical data strongly support selective COX-2 inhibitors acting as radiosensitizers.
- The combination of radiotherapy with COX-2 inhibition holds significant clinical potential for cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists